Skip to content
Oncology Research Hub

Boston, Massachusetts

Cancer clinical trials in Boston, MA

467 cancer studies are recruiting participants at sites in Boston as of November 16, 2026, according to ClinicalTrials.gov. Oncology Research Hub can help you understand your options and connect with a study team.

Call (888) 343-1186
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Boston at a glance

  • 467 studies are recruiting at a site in Boston.
  • By phase: Early Phase 1 (2), Phase 1 (86), Phase 1/2 (90), Phase 2 (99), Phase 2/3 (8), Phase 3 (71), Phase 4 (8), No phase (59), Observational (44). Studies of devices and behavioral approaches have no phase.
  • By sponsor: industry (246), university, hospital or other (198), government (23).
  • By research area: Breast Cancer (143), Lung Cancer (126), Lymphoma (105), Prostate Cancer (48), Pancreatic Cancer (26), Melanoma (19).
  • Most recent update to one of these records: November 16, 2026.

Breast cancer studies recruiting in Boston

Basic details from each study's public record (the 30 most recently updated of 467). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Boehringer Ingelheim
    Study site
    Dana-Farber Cancer Institute
    Registry record
    NCT06324357 · updated
  2. Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Dana-Farber Cancer Institute ( Site 0050)
    Registry record
    NCT06686394 · updated
  3. Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    LeonaBio
    Study sites
    Dana-Farber Cancer Institute · Massachusetts General Hospital
    Registry record
    NCT05696626 · updated
  4. A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Hoffmann-La Roche
    Study site
    Dana Farber Cancer Institute
    Registry record
    NCT05894239 · updated
  5. Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors

    • Phase 1
    • Ages 12 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Dana-Farber Cancer Institute
    Registry record
    NCT05372640 · updated
  6. Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Dana-Farber Cancer Institute
    Registry record
    NCT05422794 · updated
  7. Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

    • Phase 2
    • All ages
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Dana-Farber Cancer Institute · Tufts Medical Center
    Registry record
    NCT05564377 · updated
  8. Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Tufts Medical Center
    Registry record
    NCT06058377 · updated

Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Boston, MA on ClinicalTrials.gov.

Lung cancer studies recruiting in Boston

  1. A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors

    • Phase 1
    • Ages 18 to 99
    • All sexes
    Sponsor
    Erasca, Inc.
    Study sites
    Dana Farber Cancer Institute · Massachusetts General Hospital (MG)
    Registry record
    NCT06983743 · updated
  2. EQUAL: EGFR ctDNA QUantative Assessment for Lung Cancer Screening in Asian and Latinx Populations

    • No phase
    • Ages 40 to 80
    • All sexes
    Sponsor
    Dana-Farber Cancer Institute
    Study site
    Dana-Farber Cancer Institute
    Registry record
    NCT06716580 · updated
  3. A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

    • Phase 2/3
    • Ages 18 and older
    • All sexes
    Sponsor
    Bristol-Myers Squibb
    Study site
    Dana-Farber Cancer Institute
    Registry record
    NCT07063745 · updated
  4. A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    BioNTech SE
    Study site
    Dana-Farber Cancer Institute
    Registry record
    NCT07111520 · updated
  5. Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Beth Israel Deaconess Medical Center · Boston Medical Center · Dana-Farber Cancer Institute
    Registry record
    NCT04267848 · updated
  6. Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Dana-Farber Cancer Institute
    Registry record
    NCT04665739 · updated
  7. Testing Tumor Tissue and Blood to Help Select Personalized Treatments for Patients With Suspected Lung Cancers

    • Observational
    • All ages
    • All sexes
    Sponsor
    Lung Cancer Mutation Consortium
    Study sites
    Beth Israel Deaconess Medical Center · Boston Medical Center · Brigham and Women's Hospital
    Registry record
    NCT04712877 · updated
  8. Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

    • Phase 3
    • Ages 70 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Tufts Medical Center
    Registry record
    NCT06096844 · updated

Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Boston, MA on ClinicalTrials.gov.

Prostate cancer studies recruiting in Boston

  1. The Prostate Cancer, Genetic Risk, and Equitable Screening Study (ProGRESS)

    • No phase
    • Ages 55 to 69
    • Male participants
    Sponsor
    VA Office of Research and Development
    Study site
    VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA
    Registry record
    NCT05926102 · updated

Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Boston, MA on ClinicalTrials.gov.

Melanoma studies recruiting in Boston

  1. A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)

    • Phase 1/2
    • From 6 months, up to 17 years
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Call for Information (Investigational Site 0026)
    Registry record
    NCT02332668 · updated

Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in Boston, MA on ClinicalTrials.gov.

Lymphoma studies recruiting in Boston

  1. A Multicenter Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-Cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymph...

    • No phase
    • Ages 1 to 25
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Dana-Farber/Boston Children s Hospital
    Registry record
    NCT05621291 · updated
  2. Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Hoffmann-La Roche
    Study site
    Boston Medical Center
    Registry record
    NCT06806033 · updated
  3. A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study sites
    Beth Israel Deaconess Medical Center ( Site 0161) · Dana Farber Cancer Institute ( Site 0111)
    Registry record
    NCT06890884 · updated
  4. Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Dana-Farber Cancer Institute · Tufts Medical Center
    Registry record
    NCT04269902 · updated
  5. A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

    • Phase 3
    • Ages 5 to 60
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Dana-Farber Cancer Institute
    Registry record
    NCT05675410 · updated
  6. A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Regeneron Pharmaceuticals
    Study site
    Beth Israel Deaconess Medical Center
    Registry record
    NCT06091254 · updated
  7. A Phase 2 Study of Epcoritamab in Patients With Follicular Lymphoma and Marginal Zone Lymphoma Not Accomplishing a Complete Response With Upfront Therapy

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Beth Israel Deaconess Medical Center
    Study site
    Beth Israel Deaconess Medical Center
    Registry record
    NCT06510361 · updated

Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Boston, MA on ClinicalTrials.gov.

Pancreatic cancer studies recruiting in Boston

  1. Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)

    • Phase 2
    • Ages 12 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Massachusetts General Hospital ( Site 0111)
    Registry record
    NCT04924075 · updated
  2. A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Astellas Pharma Global Development, Inc.
    Study site
    Massachusetts General Hospital
    Registry record
    NCT07024615 · updated
  3. A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Incyte Corporation
    Study site
    Investigative Site US022
    Registry record
    NCT07522073 · updated
  4. A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Verastem, Inc.
    Study sites
    Dana-Farber Cancer Institute · Massachusetts General Hospital
    Registry record
    NCT07644559 · updated
  5. Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Dana-Farber Cancer Institute
    Registry record
    NCT05372614 · updated

Source: ClinicalTrials.gov. Data processed . See every pancreatic cancer study recruiting in Boston, MA on ClinicalTrials.gov.

Ask about studies near Boston

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 16, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded.

Oncology Research Hub does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 343-1186

or send a short form

How should we reach you?

Call